Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of Vitamin D and Effect on Heart Disease and Insulin Resistance

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Grace McComsey, University Hospital Case Medical Center
ClinicalTrials.gov Identifier:
NCT01093417
First received: March 24, 2010
Last updated: June 14, 2016
Last verified: June 2016
Results First Received: January 28, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator)
Conditions: Human Immunodeficiency Virus (HIV)
Vitamin D Deficiency
HIV Infections
Interventions: Drug: Vitamin D
Other: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Placebo 15 participants were randomized to matching placebo for 12 weeks
Vitamin D 4000 IU 30 participants were randomized to 4000IU of cholecalciferol (vitamin D3) daily for 12 weeks

Participant Flow:   Overall Study
    Placebo   Vitamin D 4000 IU
STARTED   15   30 
COMPLETED   15   29 
NOT COMPLETED   0   1 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Placebo 15 participants were randomized to matching placebo for 12 weeks
Vitamin D 4000 IU 30 participants were randomized to 4000IU of cholecalciferol (vitamin D3) daily for 12 weeks
Total Total of all reporting groups

Baseline Measures
   Placebo   Vitamin D 4000 IU   Total 
Overall Participants Analyzed 
[Units: Participants]
 15   30   45 
Age 
[Units: Participants]
     
<=18 years   0   0   0 
Between 18 and 65 years   15   30   45 
>=65 years   0   0   0 
Age 
[Units: Years]
Mean (Standard Deviation)
 40  (10)   47  (8)   45  (9) 
Gender 
[Units: Participants]
     
Female   5   5   10 
Male   10   25   35 
Region of Enrollment 
[Units: Participants]
     
United States   15   30   45 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Change in Endothelial Function   [ Time Frame: Baseline and 12 weeks ]

2.  Secondary:   Change in Serum 25-hydroxyvitamin D Concentration in Both Groups   [ Time Frame: Baseline and 12 weeks ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Grace McComsey, MD
Organization: University Hospitals Case Medical Center
phone: 2168443607
e-mail: gam9@case.edu


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Grace McComsey, University Hospital Case Medical Center
ClinicalTrials.gov Identifier: NCT01093417     History of Changes
Other Study ID Numbers: 11-09-30
Study First Received: March 24, 2010
Results First Received: January 28, 2012
Last Updated: June 14, 2016
Health Authority: USA:Internal Review Board